GSK hopes for Arexvy boost after positive Phase III data
UK-based GSK (LSE: GSK) has announced new data from its Phase III trial of Arexvy (RSV vaccine), presented at the 2024 CHEST annual meeting.
The trial, which examined the vaccine’s safety and efficacy against lower respiratory tract disease (LRTD) caused by RSV, showed that a single dose of the vaccine maintained protection across three full RSV seasons.
Arexvy was first approved by the US Food and Drug Administration in 2023 to prevent LRTD in individuals aged 60 and older. GSK subsequently expanded its use to adults aged 50 to 59 with a high risk of severe RSV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze